Methodological considerations in the interpretation of ASCENT-03
European Journal of Cancer · 2026-09 · 245 · 116962
DOI: 10.1016/j.ejca.2026.116962 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-09. Verfasst von Francesca Poggio und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinica di Oncologia Medica, AOM - IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: francescabenedetta.poggio@aomliguria.it. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Camptothecin, Antibodies, Monoclonal, Humanized, Randomized Controlled Trials as Topic. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Results of the ASCENT-03 trial demonstrated a statistically significant improvement in progression-free survival with sacituzumab govitecan (SG) compared with chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (mTNBC) ineligible for PD-(L)1 inhibitors. This population represents a clear unmet need, as PD-L1 CPS < 10 tumours account for a substantial proportion of mTNBC and many patients do not receive subsequent lines of therapy. However, several methodological considerations temper the strength of the conclusions, underlining the need for mature, crossover-adjusted overall survival analyses before definitively establishing SG as a first-line standard of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinica di Oncologia Medica, AOM - IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: francescabenedetta.poggio@aomliguria.it.
- Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
Zitieren
APA
Poggio, F., & Generali, D. (2026). Methodological considerations in the interpretation of ASCENT-03. European Journal of Cancer, 245, 116962. https://doi.org/10.1016/j.ejca.2026.116962
Vancouver
Poggio F, Generali D. Methodological considerations in the interpretation of ASCENT-03. European Journal of Cancer. 2026;245:116962. doi:10.1016/j.ejca.2026.116962
BibTeX
@article{Poggio2026,
author = {Poggio, Francesca and Generali, Daniele},
title = {Methodological considerations in the interpretation of ASCENT-03},
journal = {European Journal of Cancer},
year = {2026},
volume = {245},
pages = {116962},
doi = {10.1016/j.ejca.2026.116962}
}
EUVIMED